



**THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant : Charles D. Y. Sia Confirmation No.: 4350  
Appl'n No. : 09/055,744  
Filed : April 7, 1998  
Title : HIV-SPECIFIC CYTOTOXIC T-CELL RESPONSES  
Grp./A.U. : 1648  
Examiner : Emily M. Le  
Docket No. : 1038-746 MIS/jb  
Customer No.. : 24223  
Date : October 27, 2004

**BY COURIER**

Mail Stop Amendment  
Commissioner of Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
U.S.A.

**AMENDMENT**

Sir:

In response to the Office Action of May 27, 2004, please amend the  
above-identified application as follows:

Amendments to the Specification begin on page 2 of this paper.

Amendments to the Claims are reflected in the listing of claims which  
begins on page 3 of this paper.

Remarks/Arguments begin on page 5 of this paper.

11/03/2004 MBLAND 00000005 09055744

01 FC:1253

980.00 QP

**REMARKS/ARGUMENTS**

Petition is hereby made under the provisions of 37 CFR 1.136(a) for an extension of three months of the period for response to the Office Action. Our cheque in respect of the prescribed fee is enclosed.

The Examiner considered that the Voluntary Amendment, presumably that submitted June 11, 1999, failed to place the application into sequence compliance.

In particular, the Examiner indicated that the Sequence pages contain new matter, in that the contents disclosed therein do not match those presented in the original specification. The Examiner indicated that SEQ ID No:9 as contained in the Sequence Listing contains 65 amino acids whereas the sequence identified in Table 2, page 17 as being SEQ ID No:9, contains 67 amino acids.

Submitted herewith is a substitute Sequence Listing in hard copy and computer-readable forms. It is hereby stated that the Sequence Listing in hard copy and computer-readable forms are the same and involve no new matter. This Amendment includes direction to substitute the hard copy of the Sequence Listing for the existing one.

Upon examination of the Sequence Listing, it was found that two amino acids had been inadvertently omitted between amino acids 47 and 48 in the Sequence Listing. This matter has been corrected on the enclosed substitute Sequence Listing.

It is submitted that the application is now sequence compliant.

The Examiner required submission of new corrected drawings because the current drawings contain text which is not clearly written, pointing to Figure 2.

This rejection is a provisional one, since the conflicting claims have not yet been patented. The matter may, therefore, be deferred to a later time.

It is believed that this application is now in condition for allowance and early and favourable consideration and allowance are respectfully solicited.

Respectfully submitted,



---

Michael I. Stewart  
Reg. No. 24,973

Toronto, Ontario, Canada,  
(416) 595-1155  
FAX No. (416) 595-1163